Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

Written by Emily J. Thompson, Senior Investment Analyst

ACHL%

Source: Newsfilter

Updated: Nov 19 2024

0mins

Source: Newsfilter

Company Listing Update: Achilles Therapeutics has successfully transferred its American Depositary Shares listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective November 19, 2024, allowing an additional 180 days to meet compliance with minimum bid price requirements.
Business Focus: The company specializes in developing AI-powered precision T cell therapies targeting unique cancer markers, utilizing patient-specific DNA sequencing data for treatment development.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Dogecoin Surges 8% to Nearly $0.15 Due to New Senate Crypto Bill Draft

Disney's 17.2 P/E Ratio Suggests Greater Potential than Netflix

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch